aspirin

P3, N=360, Completed, Oslo University Hospital | Recruiting --> Completed | Trial completion date: Nov 2026 --> Jun 2026 | Trial primary completion date: Nov 2026 --> Jun 2026

P4, N=1148, Recruiting, Assistance Publique - Hôpitaux de Paris | Not yet recruiting --> Recruiting | Trial completion date: Mar 2028 --> Dec 2028 | Trial primary completion date: Sep 2025 --> Dec 2028

Colorectal cancer treatment is increasingly evolving into a precision oncology approach. Integration of molecular biomarkers enables tailored therapy decisions and opens new options, particularly in adjuvant and metastatic settings.

P4, N=60, Completed, Kaohsiung Veterans General Hospital.

P2, N=426, Terminated, Fundació Institut Germans Trias i Pujol | Recruiting --> Terminated; The impact of the COVID-19 pandemic on TB diagnosis affected greatly the recruitment rate and posed challenges to the trial's timeline, consuming the funding needed to continue the enrolment.

P3, N=586, Not yet recruiting, The First Affiliated Hospital of Zhengzhou University

P=N/A, N=1000, Not yet recruiting, Massachusetts General Hospital

Modern treatment approaches, including therapeutic phlebotomy, low-dose aspirin, and cytoreductive therapies (hydroxyurea, interferon-α formulations, and ruxolitinib), have reduced blood cell counts and thrombotic risk, yet concerns about treatment-associated cardiovascular toxicity have emerged. Recent cardio-oncology guidelines emphasize structured monitoring for cancer therapy-related cardiovascular toxicity. This mini review summarizes the cardiovascular burden of PV, therapeutic strategies to mitigate risk, and emerging perspectives on cardiotoxicity-including a recently reported case of reversible left ventricular dysfunction associated with ropeginterferon α-2b.

P=N/A, N=830, Completed, Geisinger Clinic | Active, not recruiting --> Completed

Aspirin chemoprevention was widely supported despite dose variability. These findings highlight opportunities for harmonization, gene-stratified precision prevention, and higher-quality prospective evidence to guide care.

Aspirin use is also associated with significantly reduced odds of developing metastatic disease to the liver, gastrointestinal system, lungs and peritoneum in patients with colorectal cancer. These findings convey that aspirin use reduces the likelihood of in-hospital mortality, major comorbid conditions and of developing metastatic disease as compared to those who do not use aspirin.

P4, N=100, Not yet recruiting, Medical University Of Vienna